Merck KGaA Company Profile (OTCMKTS:MKGAY)

About Merck KGaA

Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ) and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: MKGAY
  • CUSIP:
Key Metrics:
  • Previous Close: $36.18
  • 50 Day Moving Average: $35.80
  • 200 Day Moving Average: $33.91
  • 52-Week Range: $26.91 - $37.16
  • Trailing P/E Ratio: 30.46
  • Foreward P/E Ratio: 5.25
  • P/E Growth: 2.28
  • Market Cap: $46.60B
  • Outstanding Shares: 1,305,639,000
Additional Links:
Companies Related to Merck KGaA:

Analyst Ratings

Consensus Ratings for Merck KGaA (OTCMKTS:MKGAY) (?)
Ratings Breakdown: 7 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.46)
Consensus Price Target: $59.60

Analysts' Ratings History for Merck KGaA (OTCMKTS:MKGAY)
DateFirmActionRatingPrice TargetDetails
8/12/2016Berenberg BankDowngradeBuy -> HoldView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyView Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
5/17/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
5/9/2016Credit Suisse Group AGReiterated RatingNeutral$56.00 -> $57.00View Rating Details
4/16/2016Jefferies GroupReiterated RatingHold$51.00 -> $54.00View Rating Details
4/8/2016Nord/LBReiterated RatingBuyView Rating Details
4/8/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
2/6/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$60.00 -> $56.00View Rating Details
1/27/2016Bank of America Corp.Reiterated RatingNeutralView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00View Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00View Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralView Rating Details
7/2/2015Piper Jaffray Cos.Reiterated RatingUnderweightView Rating Details
6/25/2015HSBCInitiated CoverageHoldView Rating Details
4/29/2015BNP ParibasInitiated CoverageNeutralView Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Merck KGaA (OTCMKTS:MKGAY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Merck KGaA (OTCMKTS:MKGAY)
Current Year EPS Consensus Estimate: $6.53 EPS
Next Year EPS Consensus Estimate: $6.80 EPS


Dividend History for Merck KGaA (OTCMKTS:MKGAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merck KGaA (OTCMKTS:MKGAY)
No insider trades for this company have been tracked by


Latest Headlines for Merck KGaA (OTCMKTS:MKGAY)
DateHeadline logoMerck Showcases Innovative Effect Pigments and Processes at K2016 (OTCMKTS:MKGAY) - October 18 at 6:02 PM logoMerck Expands Biotech Production Capacity in Spain (OTCMKTS:MKGAY) - October 17 at 6:03 PM logoMerck Grants Rights to tutoProm™ Surface Coatings to durXtreme (OTCMKTS:MKGAY) - October 17 at 11:11 AM logoCHMP Adopts Positive Opinion of Metformin, Including Merck’s Type 2 Diabetes Treatment Portfolio, in Patients with Renal Impairment (OTCMKTS:MKGAY) - October 14 at 5:58 PM logoMerck Sets its Sights on 2018 and Outlines Future Strategic Roadmap (OTCMKTS:MKGAY) - October 13 at 9:44 AM logoMerck Publishes First International Curiosity Study (OTCMKTS:MKGAY) - October 12 at 11:29 AM logoMerck Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award (OTCMKTS:MKGAY) - October 10 at 10:50 AM logoMerck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award (OTCMKTS:MKGAY) - October 10 at 10:50 AM logoMerck KgaA's MilliporeSigma Opens M Lab Collaboration Center In Korea (OTCMKTS:MKGAY) - October 6 at 11:40 AM logoMerck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 (OTCMKTS:MKGAY) - September 28 at 11:06 AM logoMerck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 (OTCMKTS:MKGAY) - September 28 at 11:06 AM logoShire returns rights to Humira biosimilar to Momenta Pharma (OTCMKTS:MKGAY) - September 27 at 6:02 PM logoMerck KGaA, Darmstadt, Germany and the Royal Health Awareness Society Partner to Advance Women's Health in Jordan (OTCMKTS:MKGAY) - September 22 at 5:52 PM logoMerck Invests over € 50 million in Flagship Pharmaceutical Packaging Building in Darmstadt (OTCMKTS:MKGAY) - September 21 at 5:52 PM logoMerck’s New Steritest™ Symbio Pump Accessories Enable Faster, Safer Sterility Testing in Any Setting (OTCMKTS:MKGAY) - September 19 at 6:09 PM logoMerck Presents New Data Examining Durable Efficacy with Investigational Cladribine Tablets in Multiple Sclerosis (OTCMKTS:MKGAY) - September 16 at 5:56 PM logo"From Glitter to Glamour" – The Merck Pigment Innovation Ronastar® Royal Sparkle (OTCMKTS:MKGAY) - September 15 at 9:35 AM logoMerck Strengthens Display Materials R&D in China (OTCMKTS:MKGAY) - September 13 at 11:00 AM logoMerck’s Consumer Health business presents new purpose to help prepare society for 100 healthy years (OTCMKTS:MKGAY) - September 13 at 11:00 AM logoMerck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif at the 2016 ECTRIMS Congress (OTCMKTS:MKGAY) - September 12 at 5:56 PM logoMerck Launches New Gene Editing Technology to Engineer Virus Resistant CHO Cell Lines (OTCMKTS:MKGAY) - September 8 at 5:57 PM logoMerck is Co-Creating the Cars of Tomorrow (OTCMKTS:MKGAY) - September 8 at 5:57 PM logoMerck KGaA -- Moody's changes outlook on Merck KGaA's ratings to stable from negative; affirms ratings (OTCMKTS:MKGAY) - August 30 at 6:10 PM logoMerck KGaA downgraded by Berenberg (OTCMKTS:MKGAY) - August 12 at 6:18 PM logoMerck Lifts Forecast Following Good Second Quarter (OTCMKTS:MKGAY) - August 10 at 9:13 AM logoMerck KGaA :MKGAY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (OTCMKTS:MKGAY) - August 9 at 6:27 PM logoMerck KGaA Q2 Net Income Down, But Raises 2016 Outlook (OTCMKTS:MKGAY) - August 4 at 9:23 AM logoMerck Invests € 15 million in Liquid Crystal Window Technology (OTCMKTS:MKGAY) - August 2 at 6:31 PM logoMerck KGaA To Provide Provantage Development & Manufacturing Services To Y-mAbs (OTCMKTS:MKGAY) - August 1 at 6:00 PM logoMerck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound (OTCMKTS:MKGAY) - August 1 at 8:11 AM logoMerck and Nanoco Sign Agreement on Eco-Friendly Quantum Materials for Displays (OTCMKTS:MKGAY) - August 1 at 2:08 AM
News IconMerck posts better-than-expected quarterly profit, revenue (OTCMKTS:MKGAY) - July 29 at 6:21 PM logoMerck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China (OTCMKTS:MKGAY) - July 28 at 2:08 AM logoMerck Biopharma Innovation Cup Honors Young Scientists (OTCMKTS:MKGAY) - July 26 at 9:08 AM logoMerck KGaA's marketing application for Cladribine tablets accepted for review in Europe (OTCMKTS:MKGAY) - July 18 at 11:30 AM logoMerck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets (OTCMKTS:MKGAY) - July 18 at 3:38 AM logoDietmar Eidens Appointed Chief HR Officer (CHRO) of Merck (OTCMKTS:MKGAY) - July 15 at 8:58 AM logoMerck Advances Water Purification Systems with New High-Throughput Line (OTCMKTS:MKGAY) - July 13 at 8:13 AM logoMerck Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables (OTCMKTS:MKGAY) - July 12 at 8:03 AM logoLate-stage study commences assessing Merck KGaA and Pfizer's avelumab + chemo in advanced ovarian cancer (OTCMKTS:MKGAY) - July 7 at 6:13 PM logoMerck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer (OTCMKTS:MKGAY) - July 6 at 8:11 AM logoMerck Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17 (OTCMKTS:MKGAY) - July 6 at 2:11 AM logoOneCrinone reproductive treatment approved in Japan (OTCMKTS:MKGAY) - July 5 at 6:00 PM logoJuniper Pharmaceuticals Says Merck, Germany, Gets Japan's Regulatory Approval For OneCrinone (OTCMKTS:MKGAY) - July 5 at 8:58 AM logoMerck and University of Nairobi to Start Medical Oncology Fellowship Program (OTCMKTS:MKGAY) - July 1 at 8:41 AM logo6:48 am Merck KGaA to present data from the pivotal Phase III TAILOR study in patients from China (OTCMKTS:MKGAY) - July 1 at 6:48 AM logoResults of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer (OTCMKTS:MKGAY) - July 1 at 4:41 AM logoSuccessful Cooperation Between Merck and Agrimer in Marine-Derived Dermocosmetic Active Ingredients (OTCMKTS:MKGAY) - July 1 at 2:11 AM logoBRIEF-Merck KGaA says Zeiss, Hamilton Thorne to join global fertility alliance (OTCMKTS:MKGAY) - June 30 at 3:48 AM logoMerck KGaA, Darmstadt, Germany, Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance (OTCMKTS:MKGAY) - June 30 at 3:15 AM


Merck KGaA (OTCMKTS:MKGAY) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff